Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas

Status unconfirmed · Phase 2

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and trastuzumab in treating patients who have metastatic cancer of the pancreas that overexpresses HER2/neu.

Key facts

Study ID: NCT00003797
Run by: Brown University
People needed: 41
Starts: 1999-03-01
Last updated by the study team: 2013-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Rush-Presbyterian-St. Luke's Medical Center — Chicago, Illinois, United States
New England Medical Center Hospital — Boston, Massachusetts, United States
St. Elizabeth's Medical Center — Boston, Massachusetts, United States
Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Mount Sinai Medical Center, NY — New York, New York, United States
University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
Memorial Hospital of Rhode Island — Pawtucket, Rhode Island, United States
Rhode Island Hospital — Providence, Rhode Island, United States
Roger Williams Medical Center/BUSM — Providence, Rhode Island, United States
Brown University Oncology Group — Providence, Rhode Island, United States
University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.